Deaths After GLP-1s; First Detransition Clinic for Youths; DXA Scans Decline

In the U.K., more than 150 deaths have been reported potentially connected to injectable weight-loss medications known as GLP-1s, according to government regulators.

Texas Children's Hospital in Houston plans to introduce the country's inaugural clinic dedicated to detransitioning transgender youth in October, as reported by Attorney General Ken Paxton.

Researchers are utilizing advanced artificial intelligence technology to identify viable sperm in men grappling with severe infertility issues, according to a report in the New York Times.

Patients who meet the Lancet Commission's clinical obesity criteria, as determined by bariatric surgery candidates, exhibited a greater disease burden, a higher surgical risk, and an elevated cardiovascular risk compared to those with preclinical obesity, according to findings published in JAMA Network Open.

A study published in JAMA Network Open cast doubt on the more intricate obesity definition proposed by the Lancet Commission.

Yet another investigation featured in JAMA Network Open revealed that a 20-week hybrid-format lifestyle program did not result in a minimum 5% reduction in total body weight among Brazilian adults struggling with obesity.

Amgen has decided to halt the development of its early-stage injectable obesity candidate, AMG 513, according to a CNBC report.

A study conducted in Denmark indicated that women who were overweight or obese during their childhood were less likely to conceive compared to those with an average body mass index, as reported in JAMA Network Open.

Bank of America's CEO disclosed that the company allocates approximately $250 million annually towards covering GLP-1 medications for its U.S. workforce, as reported by CNBC.

Research published in JAMA Internal Medicine found that higher per-patient spending in Medicare Advantage plans did not lead to improved disease outcomes for patients with type 2 diabetes.

Tirzepatide (Mounjaro), when initiated, was found to lower the risk of major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease compared to a placebo, as observed in a cohort study published in The BMJ.

Swedish registry data indicated that patients with acromegaly-associated diabetes had a higher risk of cardiovascular morbidity compared to those with type 2 diabetes, as detailed in the Journal of Clinical Endocrinology & Metabolism.

Novo Nordisk's insulin icodec (Awiqli), the first once-weekly basal insulin for adults with type 2 diabetes, is now available across the nation.

A study published in the Osteoporosis International revealed that the use of dual-energy x-ray absorptiometry (DXA) testing for osteoporosis has declined among Medicare beneficiaries over a 19-year span, with the most significant declines observed in underserved patient populations.